About Tryton
Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery.
Tryton was founded in 2003 by Aaron V. Kaplan, M.D. (Dartmouth Medical School/Dartmouth Hitchcock Medical Center) and Spray Venture Partners to develop proprietary stent technology to treat branchpoint lesions. Spray Venture Partners is a venture capital firm that has been focused exclusively on early stage medical technology companies since 1996.
The Tryton Side-Branch Stent™ is a unique balloon expandable, 5 French compatible system that is delivered with a single wire. When used in conjunction with any existing standard stent for the main vessel, it provides superior coverage and hoop strength to the origin of the sidebranch.
About Tryton: Management Team
J. Greg Davis – Chief Executive Officer
.jpg)
Mr. Greg Davis is an experienced medical device executive with broad global and functional experience in finance, manufacturing, sales and general management. Prior to joining Tryton Medical, Greg was President of Guidant, Japan with profit and loss responsibility for the company’s $225 million cardiovascular business. Prior to his work in Japan, Greg managed Guidant’s product portfolio in 13 Asian countries. He was also instrumental in the start up and management of an FDA-regulated, Class III manufacturing facility in Dorado, Puerto Rico. Greg started his career in various financial management roles with Cardiac Pacemakers Incorporated and Eli Lilly in the U.S. and Puerto Rico.
Greg holds a B.S. in mechanical engineering from the University of Minnesota and a M.B.A. from the University of Michigan.
H. Richard Davis – Chief Technical Officer
Mr. Richard Davis has over 15 years of medical device experience, primarily in the areas of general management, product development, clinical research, and operations. Throughout his career he has developed several coronary and peripheral stent designs from concept to clinical evaluation to regulatory approval and sales.
Prior to joining Tryton, Richard held positions at Cordis a Johnson and Johnson company, and Orbus Medical Technologies. During his eight years at Orbus Medical Technologies, Inc. he founded and directed its European operations including the design and formation of manufacturing facilities, sales and marketing, regulatory affairs, and clinical research groups. While at Cordis he led a team composed of representatives from clinical research, regulatory affairs, product development and manufacturing. During his tenure he was responsible for transferring technology from plants in New Jersey and Miami to Roden, the Netherlands.
Richard holds a M.S. in Mechanical Engineering from the Florida International University.
Aaron Kaplan, M.D., F.A.C.C.
Dr. Aaron V.Kaplan is Associate Professor of Medicine (Dartmouth Medical School) and Director of Research, Cardiac Catheterization Laboratories (Dartmouth-Hitchcock Medical Center). In addition to his clinical responsibilities, Dr. Kaplan supervises Cardiology Fellows, chairs the Dartmouth Device Development Symposia and lectures regularly at the Tuck School. Prior to joining the Dartmouth Faculty, Dr. Kaplan was Director of Interventional Cardiology at the Palo Alto VA and served on the faculty at Stanford. Dr. Kaplan has over 40 publications and is on the Editorial Board of Cardiac Catheterization and Intervention.
He focuses on early-stage medical device development and has been on the founding team of a number of venture backed medical device companies including LocalMed and Perclose. In addition, Dr. Kaplan has consulted to NMT Medical, Guidant Corporation, Johnson & Johnson and was an Entrepreneur-In-Residence at Three Arch Partners. Dr. Kaplan has authored over 18 U.S. Patents
He received a B.S. from Tufts University, M.D. at Wake Forest University, medical training at Northwestern University and cardiology training at Stanford University.
Dan Cole – General Partner (Spray Venture Partners)
Dan Cole joined Spray Venture Partners at its founding in 1996. Dan brings twenty years of medical device operational experience to Spray Venture Partners. Dan has served on the Boards of 10 companies in the first Spray fund, two of which he started. Prior to joining Spray, Dan served as Senior Vice President and Group President of Boston Scientific Corporation's vascular business, a $1.2 billion group including SCIMED (cardiology), Medi-tech (radiology), Meadox (vascular surgery), and EP Technologies (electro psychology). He was also responsible for BSC's rapidly growing international operations. Dan was previously President and Chief Operating Officer of SCIMED Life Systems, a public company with revenues of $260 million in 1994 prior to the company's merger with Boston Scientific in 1995. He previously held a variety of executive and general management positions at Baxter Healthcare Divisions.
He serves on the Board of Directors of Acorn Cardiovascular, Direct Flow Medical, Facet Solutions, Kolis Scientific, PneumRx and Thoratec Laboratories.
He earned a B.S. in Aeronautical Engineering from the University of Kansas, an M.S. in Aeronautical Engineering from the United States Navy Post-Graduate School, and an M.B.A. from the University of California, Los Angeles.